David Tellekson

David Tellekson

Fenwick & West LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Litigation Alert: Supreme Court Rules on “Reverse Payment” Settlements in Federal Trade Commission v. Actavis, Inc.

Today, the U.S. Supreme Court held in Federal Trade Commission v. Actavis, Inc. that so-called “reverse payment” settlement agreements should be analyzed under a rule-of-reason analysis under which the court assesses any...more

6/18/2013 - ANDA Anti-Competitive Antitrust Litigation FTC FTC v Actavis Hatch-Waxman Patents Pharmaceutical Reverse Payment Settlement Agreements SCOTUS

Intellectual Property Bulletin Winter 2013: Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor

On January 14, 2013, the U.S. Supreme Court refused to consider the U.S. Court of Appeals for the Federal Circuit's exclusion in Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011), of post-approval...more

4/5/2013 - Biogen Idec Classen Immunotherapies FDA GlaxoSmithKline Infringement Patents Safe Harbors SCOTUS

Intellectual Property Bulletin - Winter 2013

In This Bulletin: - Just Moot It: Supreme Court in Already v. Nike Clarifies When a Covenant Not to Sue Can Kill a Declaratory Judgment Case - Murky Waters: Post-Approval Regulatory Activities and the §...more

4/4/2013 - Covenant Not to Sue Drug Manufacturers FDA Generic Drugs Mootness Nike Public Performance Rights Safe Harbors SCOTUS Standing Trade Secrets Trademarks Transfer of Venue

Litigation Alert: U.S. Supreme Court to Weigh In on Reverse Payment Deals

On March 25, 2013, the U.S. Supreme Court heard oral argument in FTC v. Actavis, Inc.,1 which is on appeal from the U.S. Court of Appeals for the Eleventh Circuit. This case addresses a type of patent litigation settlement...more

4/3/2013 - FDA FTC v Actavis Generic Drugs Patents Pay-For-Delay Pharmaceutical Pharmaceutical Patents Reverse Payment Settlement Agreements SCOTUS

4 Results
|
View per page
Page: of 1